Thrombophilia and arteriovenous fistula survival in esrd

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 6, 2013, Pages 962-968

  Salmela, Birgitta ^a   Hartman, Jari ^b   Peltonen, Seija ^b   Albäck, Anders ^c   Lassila, Riitta ^c  

^a Department of Hematology   (United States)

^b Division of Internal Medicine   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8C; CARDIOLIPIN ANTIBODY; D DIMER; FIBRINOGEN; HOMOCYSTEINE; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S;

ADOLESCENT; ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; COMORBIDITY; DIABETES MELLITUS; DISEASE SURVEILLANCE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUTATION; OBSERVATIONAL STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RISK FACTOR; SCREENING; SURVIVAL; THROMBIN TIME; THROMBOPHILIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTERIOVENOUS SHUNT, SURGICAL; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CHI-SQUARE DISTRIBUTION; DIABETES COMPLICATIONS; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GRAFT OCCLUSION, VASCULAR; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RISK FACTORS; SEX FACTORS; THROMBOPHILIA; TREATMENT OUTCOME; VASCULAR PATENCY; YOUNG ADULT;

EID: 84878821940     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03860412     Document Type: Article

References (37)

1. Feldman HI, Kobrin S, Wasserstein A: Hemodialysis vascular access morbidity. J Am Soc Nephrol 7: 523-535, 1996
2. Knoll GA, Wells PS, Young D, Perkins SL, Pilkey RM, Clinch JJ, Rodger MA: Thrombophilia and the risk for hemodialysis vascular access thrombosis. J AmSoc Nephrol 16: 1108-1114, 2005
3. Roy-Chaudhury P, Sukhatme VP, Cheung AK: Hemodialysis vascular access dysfunction: A cellular and molecular viewpoint. J Am Soc Nephrol 17: 1112-1127, 2006
4. Födinger M,Mannhalter C, Pabinger I, Koizar D, Rintelen C,Hörl WH, Sunder-Plassmann G: Resistance to activated protein C (APC): Mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. Nephrol Dial Transplant 11: 668-672, 1996
5. LeSar CJ, Merrick HW, Smith MR: Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. J Am Coll Surg 189: 73-79, discussion 79-81, 1999
6. Manns BJ, Burgess ED, Parsons HG, Schaefer JP, Hyndman ME, Scott-Douglas NW: Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int 55: 315-320, 1999
7. Valeri A, Joseph R, Radhakrishnan J: A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis patients. Clin Nephrol 51: 116-121, 1999
8. Adler S, Szczech L, Qureshi A, Bollu R, Thomas-John R: IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis. Clin Nephrol 56: 428-434, 2001
9. Atac ̧ B, Yakupo-glu U, Ozbek N, Ozdemir FN, Bilgin N: Role of genetic mutations in vascular access thrombosis among hemodialysis patients waiting for renal transplantation. Transplant Proc 34: 2030-2032, 2002
10. Mallamaci F, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Candela V, Scudo P, Spoto B, Testa A, Tripepi G, Tech S, Zoccali C: Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients. Am J Kidney Dis 45: 702-707, 2005
11. Ghisdal L, Broeders N, Wissing K.M, Mena J.M, Lemy A, Wijns W, Pradier O, Donckier V, Racapé J, Vereerstraeten P, Abramowicz D: Thrombophilic factors in stage V chronic kidney disease patients are largely corrected by renal transplantation.Nephrol Dial Transplant 26: 2700-2705, 2011
12. Huijbregts H.J, Bots M.L, Wittens C.H, Schrama Y.C, Moll F.L, Blankestijn P.J; CIMINO study group: Hemodialysis arteriovenous fistula patency revisited: Results of a prospective, multicenter initiative. Clin J Am Soc Nephrol 3: 714-719, 2008
13. Rosendaal FR: Venous thrombosis: a multicausal disease. Lancet 353: 1167-1173, 1999
14. Vig S, Chitolie A, Sleight S, Bevan D, Dormandy J, Thompson MM, Halliday A: Prevalence and risk of thrombophilia defects in vascular patients. Eur J Vasc Endovasc Surg 28: 124-131, 2004
15. Corti R, Hutter R, Badimon JJ, Fuster V: Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis 17: 35-44, 2004
16. Esmon CT: Inflammation and thrombosis. J Thromb Haemost 1: 1343-1348, 2003
17. Esmon CT: Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 32[Suppl 1]: 49-60, 2006
18. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B: Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. JAMA 293: 1737-1745, 2005
19. Wannamethee SG, Shaper AG, Lowe GD, Lennon L, Rumley A, Whincup PH: Renal function and cardiovascular mortality in elderly men: The role of inflammatory, procoagulant, and endothelial biomarkers. Eur Heart J 27: 2975-2981, 2006
20. Kirmizis D, Tsiandoulas A, Pangalou M, Koutoupa E, Rozi P, Protopappa M, Barboutis K: Validity of plasma fibrinogen, Ddimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis. Med Sci Monit 12: 55-62, 2006
21. Miller PE, Tolwani A, Luscy CP, Deierhoi MH, Bailey R, Redden DT, Allon M: Predictors of adequacy of arteriovenous fistulas in hemodialysis patients. Kidney Int 56: 275-280, 1999
22. Miller CD, Robbin ML, Allon M: Gender differences in outcomes of arteriovenous fistulas in hemodialysis patients. Kidney Int 63: 346-352, 2003
23. Yevzlin AS, Conley EL, Sanchez RJ, Young HN, Becker BN: Vascular access outcomes and medication use: a USRDS study. Semin Dial 19: 535-539, 2006
24. Gibson KD, Gillen DL, Caps MT, Kohler TR, Sherrard DJ, Stehman-Breen CO: Vascular access survival and incidence of revisions: A comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States RenalData SystemDialysis Morbidity and Mortality Study. J Vasc Surg 34: 694-700, 2001
25. Diehm N, van den Berg JC, Schnyder V, Bühler J, Willenberg T, Widmer M, Mohaupt MG, Baumgartner I: Determinants of haemodialysis access survival. Vasa 39: 133-139, 2010
26. Monroy-Cuadros M, Yilmaz S, Salazar-Ba~nuelos A, Doig C: Risk factors associatedwith patency loss of hemodialysis vascular access within 6 months. Clin J Am Soc Nephrol 5: 1787-1792, 2010
27. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL: Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA 295: 306-313, 2006
28. Mitsiev I, Reinhold S, Ziemer S, Neumayer HH, Hocher B: Combination of APC resistance and acquired protein S deficiency in a haemodialysis patient with recurrent A-V shunt thrombosis. Nephrol Dial Transplant 14: 2474-2477, 1999
29. O'Shea SI, Lawson JH, Reddan D, Murphy M, Ortel TL: Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg 38: 541-548, 2003
30. Kaufman JS: Antithrombotic agents and the prevention of access thrombosis. Semin Dial 13: 40-46, 2000
31. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, Goldfarb DS, Peduzzi PN; Veterans Affairs Cooperative Study Group on Hemodialysis Access Graft Thrombosis: Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 14: 2313-2321, 2003
32. Dember LM, Beck GJ, Allon M, Delmez JA, Dixon B.S, Greenberg A, Himmelfarb J, Vazquez MA, Gassman JJ, Greene T, Radeva MK, Braden GL, Ikizler TA, Rocco MV, Davidson IJ, Kaufman JS, Meyers CM, Kusek JW, Feldman HI; Dialysis Access Consortium Study Group: Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: A randomized controlled trial. JAMA 299: 2164-2171, 2008
33. Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, Dember LM, Himmelfarb J, Gassman JJ, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Fenves AZ, Kaufman JS, Cotton JR Jr, Martin KJ, McNeil JW, Rahman A, Lawson JH, Whiting JF, Hu B, Meyers CM, Kusek JW, Feldman HI; DAC Study Group: Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med 360: 2191-2201, 2009
34. Dixon BS, Beck GJ, Dember LM, Vazquez MA, Greenberg A, Delmez JA, Allon M, Himmelfarb J, Hu B, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Lawson JH, Cotton JR Jr, Kusek JW, Feldman HI; Dialysis Access Consortium (DAC) Study Group: Use of aspirin associates with longer primary patency of hemodialysis grafts. J Am Soc Nephrol 22: 773-781, 2011
35. Hasegawa T, Elder SJ, Bragg-Gresham JL, Pisoni RL, Yamazaki S, Akizawa T, Jadoul M, Hugh RC, Port FK, Fukuhara S: Consistent aspirin use associated with improved arteriovenous fistula survival among incident hemodialysis patients in the dialysis outcomes and practice patterns study. Clin J Am Soc Nephrol 3: 1373-1378, 2008
36. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, Pekkanen J, D'Agostino R, Kannel WB, Wilson PW, Tofler G, Arocha-Pinango CL, Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriquez-Roa E, Ryder E, Diez-Ewald MP, Campos G, Fernandez V, Torres E, Marchioli R, Valagussa F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen JT, Nyyssönen K, Tuomainen TP, Hedblad B, Lind P, Loewel H, Koenig W, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Després JP, Dagenais GR, Tunstall-Pedoe H, Woodward M, Ben-Shlomo Y, Davey Smith G, Palmieri V, Yeh JL, Rudnicka A, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Kromhout D, Dickinson A, Ireland B, Juzwishin K, Kaptoge S, Lewington S, Memon A, Sarwar N, Walker M, Wheeler J, White I, Wood A; Fibrinogen Studies Collaboration: Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294: 1799- 1809, 2005
37. Jenkins PV, Rawley O, Smith OP, O'Donnell JS: Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol 157: 653-663, 2012